Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC 50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl , respectivelyIn VitroLisaftoclax (compound 6) exhibits IC 50 values of 5.5 nM and 6.4 nM in Bcl-2 dependent RS4;11 cells and Bcl-xl dependent Molm13 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Bcl-2 2 nM (IC 50 ) Bcl-xL 5.9 nM (IC 50 ).
Specifications and Purity: ≥99%
Molecular Formula: C45H48ClN7O8S
Molecular Weight: 882.42
PubChem CID: 137355972
Isomeric SMILES: C1CC2(C1)CCC(=C(C2)C3=CC=C(C=C3)Cl)CN4CCN(CC4)C5=CC(=C(C=C5)C(=O)NS(=O)(=O)C6=CC(=C(C=C6)NC[C@H]7COCCO7)[N+](=O)[O-])OC8=CN=C9C(=C8)C=CN9
- UPC:
- 85121808
- Condition:
- New
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- L650177-5mg
- CAS:
- 2180923-05-9
- Product Size:
- 5mg
akash.verma@cenmed.com
(732) 447-1115





